Hepatitis A Vaccine Market Size, Share, Growth, Trends and Industry Analysis, By Type (Inactivated Vaccine, Live Attenuated Vaccine), By Application (Government Institution, Private Sector, Other), Regional Insights and Forecast From 2025 to 2033

• 

  Request a Free sample to learn more about this report

HEPATITIS A VACCINE MARKET OVERVIEW

The global hepatitis a vaccine market size, valued at USD 0.76 billion in 2024, is expected to climb to USD 0.94 billion by 2033 at a CAGR of 2.2% during the forecast period from 2025 to 2033.

The hepatitis A vaccine is an effective way to protect against the highly contagious hepatitis A virus, which affects the liver. It comes in two main types, an inactivated vaccine and a combination vaccine that provides protection against both hepatitis A and hepatitis B. The vaccine is recommended for individuals of all ages, especially those at higher risk, including travelers to regions with poor sanitation, individuals with chronic liver disease, and men who have sex with men. The vaccine typically requires two doses, with long-lasting immunity often extending beyond 20 years.

Common side effects are mild and temporary, making the hepatitis A vaccine a crucial tool in preventing this liver infection and its potential complications. To determine vaccination eligibility and schedule, it's essential to consult with a healthcare provider who can assess individual risk factors and adhere to local vaccination guidelines. Ultimately, the hepatitis A vaccine plays a significant role in public health by reducing the spread of the virus and minimizing the risks associated with hepatitis A infection.

COVID-19 IMPACT

Disruption in Routine Vaccination Programs to Hamper Demand Significantly

The COVID-19 pandemic has been unprecedented and staggering, with hepatitis A vaccine experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

COVID-19 had a life changing impact globally. The hepatitis A vaccine market growth was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for hepatitis A vaccine share experienced a reduced demand.

During a pandemic, healthcare systems often redirect resources, including personnel and supplies, to respond to the immediate crisis. This can disrupt routine vaccination programs, including those for hepatitis A, as healthcare facilities may prioritize pandemic-related care and vaccination efforts. The production and distribution of vaccines can be affected by disruptions in global supply chains and limitations in manufacturing capacities, especially when healthcare systems are overwhelmed during a pandemic. This can potentially lead to shortages of vaccines, including the hepatitis A vaccine.

Public health measures, such as lockdowns and restrictions on movement, can hinder individuals' ability to access healthcare services, including vaccinations. Fear of contracting COVID-19 at healthcare facilities may also lead to vaccine hesitancy, causing some individuals to delay or skip routine vaccinations like hepatitis A. Governments and public health agencies may temporarily shift their priorities during a pandemic to focus on responding to the immediate crisis. This shift in focus may result in reduced promotion and awareness campaigns for other vaccines, including hepatitis A. The market is anticipated to boost the hepatitis A vaccine market growth following the pandemic.

LATEST TRENDS

Global Efforts for Elimination to Broaden Market Growth

Various countries and regions were working toward the elimination of hepatitis A as a public health threat. This includes implementing mass vaccination campaigns in areas with high disease burden and promoting vaccination among high-risk populations. Pharmaceutical companies were exploring and developing combination vaccines that provide protection against both hepatitis A and hepatitis B in a single shot. These combination vaccines simplify vaccination schedules and increase coverage against both types of hepatitis.

The importance of hepatitis A vaccination for travelers was being emphasized, especially for individuals visiting regions with a higher prevalence of the virus. Travel clinics and healthcare providers were increasingly recommending the vaccine for travelers. Efforts were being made to improve access to hepatitis A vaccination, particularly in underserved or at-risk populations. This includes making the vaccine more affordable and accessible in healthcare settings. These latest developments are anticipated to boost the hepatitis A vaccine market share.

Request a Free sample to learn more about this report

HEPATITIS A VACCINE MARKET SEGMENTATION

By Type

Based on type, the market is divided into Inactivated Vaccine and Live Attenuated Vaccine.

Inactivated Vaccine holds a major share of the global market.

By Application

Based on application, the market is bifurcated into Government Institution, Private Sector, and Other.

Government Institution as application holds a major share of the global market.

DRIVING FACTORS

Prevention of Hepatitis A Outbreaks to Boost Market Share

Hepatitis A outbreaks can occur in communities, especially when the virus is introduced into crowded or unsanitary environments. Vaccination can help prevent these outbreaks and reduce the risk of widespread infection. Hepatitis A is primarily transmitted through the consumption of contaminated food or water and through close personal contact with infected individuals. This mode of transmission makes it essential to have a vaccine to prevent the spread of the virus, particularly in settings with inadequate sanitation. These factors are anticipated to drive the hepatitis A vaccine market growth.

Protection for High-Risk Groups to Boost Market Growth

Certain populations, such as healthcare workers, men who have sex with men, individuals with chronic liver disease, and illicit drug users, are at a higher risk of hepatitis A infection. Vaccination is recommended for these groups to protect them from the virus. Public health agencies and organizations prioritize vaccination programs as part of their efforts to prevent and control infectious diseases. This includes promoting hepatitis A vaccination as part of routine immunization schedules. These factors are anticipated to drive the hepatitis A vaccine market share.

RESTRAINING FACTORS

Limited Access to Healthcare to Hamper Market Share

In some areas, limited access to healthcare services, including vaccination clinics and facilities, can hinder the availability and accessibility of the hepatitis A vaccine. People without easy access to healthcare may face barriers in obtaining the vaccine. The cost of vaccines, including the hepatitis A vaccine, can be a restraining factor, particularly for individuals without health insurance coverage. High vaccine costs can discourage some people from getting vaccinated. The factors are anticipated to hinder the growth of the hepatitis A vaccine market growth.

• Request a Free sample to learn more about this report

•  

HEPATITIS A VACCINE MARKET REGIONAL INSIGHTS

Asia Pacific Dominates the Hepatitis A Vaccine Market

Asia Pacific is the major shareholder for the hepatitis A vaccine market size. Hepatitis A is often more prevalent in regions with inadequate sanitation and limited access to clean water. In many developing and low-income countries, the virus is endemic, meaning it circulates continuously within the population. This leads to a higher burden of hepatitis A infections in these areas. In high-income countries with better sanitation and hygiene practices, hepatitis A incidence is generally lower. However, pockets of outbreaks can occur, especially among specific populations or in areas with suboptimal hygiene conditions.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

List of Top Hepatitis A Vaccine Companies

• Glaxo Smith Kline (GSK) [U.K.]
• Merck [U.S.]
• Sanofi [France]
• Sinovac Biotech Ltd [China]
• Zhejiang Pukang [China]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.